PIOL
MCID: INT054
MIFTS: 48

Intraocular Lymphoma (PIOL)

Categories: Blood diseases, Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Intraocular Lymphoma

MalaCards integrated aliases for Intraocular Lymphoma:

Name: Intraocular Lymphoma 12 74 29 54 43 15 37 71
Primary Intraocular Lymphoma 12 58
Primary Intraocular Non-Hodgkin Malignant Lymphoma 71
Primary Intraocular Non-Hodgkin Lymphoma 58
Piol 58

Characteristics:

Orphanet epidemiological data:

58
primary intraocular lymphoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare eye diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:775
MeSH 43 D064090
NCIt 49 C9184
ICD10 via Orphanet 33 C85.7
UMLS via Orphanet 72 C0281658
Orphanet 58 ORPHA279904
UMLS 71 C0281658 C1706527

Summaries for Intraocular Lymphoma

MalaCards based summary : Intraocular Lymphoma, also known as primary intraocular lymphoma, is related to primary central nervous system lymphoma and lymphoma, hodgkin, classic. An important gene associated with Intraocular Lymphoma is CXCR5 (C-X-C Motif Chemokine Receptor 5), and among its related pathways/superpathways are PAK Pathway and Allograft rejection. The drugs Orange and Cefepime have been mentioned in the context of this disorder. Affiliated tissues include b cells, brain and eye, and related phenotypes are cellular and hematopoietic system

Wikipedia : 74 Intraocular lymphoma is a rare malignant form of eye cancer. Intraocular lymphoma may affect the eye... more...

Related Diseases for Intraocular Lymphoma

Diseases related to Intraocular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 30.6 PAX5 CXCR5 BCL6 BCL2
2 lymphoma, hodgkin, classic 30.5 PAX5 BCL6 BCL2
3 b-cell lymphoma 30.3 PAX5 CXCR5 CXCR4 BCL6 BCL2
4 diffuse large b-cell lymphoma 30.1 PAX5 IL10 CXCR4 BCL6
5 breast lymphoma 30.1 PAX5 BCL6
6 lymphoma 30.0 PAX5 IL10 CXCR5 CXCR4 BCL6 BCL2
7 peripheral t-cell lymphoma 30.0 PAX5 CXCR4 BCL6
8 human herpesvirus 8 29.9 BCL6 BCL2
9 cytomegalovirus retinitis 29.8 IL10 CXCL12
10 retina lymphoma 29.8 TRPV2 IGHV4-38-2
11 acquired immunodeficiency syndrome 29.8 IL10 CXCR5 BCL6
12 central nervous system lymphoma 29.7 PAX5 IL10 CXCR5 CXCR4 CXCL12 BCL6
13 testicular lymphoma 29.7 IGHV4-38-2 BCL6
14 marginal zone b-cell lymphoma 29.5 PAX5 IGHV4-38-2 BCL6
15 immune deficiency disease 29.0 IL10 CXCR4 CXCL12 BCL6
16 lymphoma, mucosa-associated lymphoid type 28.5 PAX5 IGHV4-38-2 CXCR5 BCL6 BCL2
17 lymphoma, non-hodgkin, familial 27.9 PAX5 IL10 IGHV4-38-2 CXCR5 CXCR4 CXCL12
18 uveitis 10.6
19 joint laxity, short stature, and myopia 10.5
20 myopia 10.5
21 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.4 CXCR5 BCL6
22 nodular lymphocyte predominant hodgkin lymphoma 10.3 PAX5 BCL6
23 lung lymphoma 10.3 PAX5 BCL6
24 bone lymphoma 10.3 PAX5 BCL6
25 paranasal sinus lymphoma 10.3 PAX5 BCL6
26 hodgkin's lymphoma, nodular sclerosis 10.3 PAX5 BCL6
27 pars planitis 10.3
28 gray zone lymphoma 10.3 PAX5 BCL6
29 aids dementia complex 10.3 CXCR4 CXCL12
30 primary cutaneous b-cell lymphoma 10.3 PAX5 BCL6
31 nodal marginal zone b-cell lymphoma 10.3 BCL6 BCL2
32 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.3 BCL6 BCL2
33 mental retardation, autosomal dominant 40 10.2 CXCR4 CXCL12
34 primary mediastinal large b-cell lymphoma 10.2 BCL6 BCL2
35 intravascular large b-cell lymphoma 10.2 BCL6 BCL2
36 follicular lymphoma 1 10.2 BCL6 BCL2
37 neuroretinitis 10.2
38 retinitis 10.2
39 astigmatism 10.2
40 degenerative myopia 10.2
41 lymphosarcoma 10.2 BCL6 BCL2
42 panuveitis 10.2
43 spherocytosis, type 5 10.1 CXCR4 CXCL12
44 neurosyphilis 10.1 IL10 CXCR5
45 macular retinal edema 10.1
46 lymphoplasmacytic lymphoma 10.1 PAX5 CXCR4 CXCL12
47 macroglobulinemia 10.1 PAX5 CXCR4 CXCL12
48 cerebral lymphoma 10.1
49 rare tumor 10.1
50 mikulicz disease 10.1 IL10 CXCR5

Graphical network of the top 20 diseases related to Intraocular Lymphoma:



Diseases related to Intraocular Lymphoma

Symptoms & Phenotypes for Intraocular Lymphoma

MGI Mouse Phenotypes related to Intraocular Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 BCL2 BCL6 CXCL12 CXCR4 CXCR5 FOLR1
2 hematopoietic system MP:0005397 9.97 ABCC1 BCL2 BCL6 CXCL12 CXCR4 CXCR5
3 immune system MP:0005387 9.91 ABCC1 BCL2 BCL6 CXCL12 CXCR4 CXCR5
4 mortality/aging MP:0010768 9.81 ABCC1 BCL2 BCL6 CXCL12 CXCR4 FOLR1
5 muscle MP:0005369 9.43 BCL2 BCL6 CXCL12 CXCR4 IL10 PAX5
6 neoplasm MP:0002006 9.02 BCL2 CXCR4 FOLR1 IL10 PAX5

Drugs & Therapeutics for Intraocular Lymphoma

Drugs for Intraocular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 3
2
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
5
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
6
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
7
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
8
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
9
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
10
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
11
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
14
Ofloxacin Approved Phase 3 82419-36-1 4583
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
17
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
18
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
19
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
20 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
21 Excitatory Amino Acid Antagonists Phase 3
22 Anesthetics, Dissociative Phase 3
23 Dermatologic Agents Phase 3
24 Antimetabolites Phase 2, Phase 3
25 Gastrointestinal Agents Phase 3
26 Hormones Phase 3
27 Antiemetics Phase 3
28 Anti-Infective Agents Phase 3
29 Etoposide phosphate Phase 2, Phase 3
30 Anti-Bacterial Agents Phase 3
31 Cola Phase 3
32 Liver Extracts Phase 3
33 Analgesics Phase 3
34 Antifungal Agents Phase 3
35 Antiparasitic Agents Phase 3
36 Neurotransmitter Agents Phase 3
37 Analgesics, Opioid Phase 3
38 Psychotropic Drugs Phase 3
39 Anti-Anxiety Agents Phase 3
40 Antipsychotic Agents Phase 3
41 Antiprotozoal Agents Phase 3
42 Narcotics Phase 3
43 Anesthetics Phase 3
44 Anesthetics, General Phase 3
45 Anesthetics, Intravenous Phase 3
46 Amebicides Phase 3
47 Liposomal amphotericin B Phase 3
48
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
50
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 153)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
2 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
5 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
6 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
7 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
8 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
9 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
10 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
11 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
12 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
13 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
14 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
16 Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
17 Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Central Nervous System Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
18 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
19 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
20 Primary Central Nervous System Non-Hodgkins's Lymphoma (PCNSL): A Phase II Clinical Trial of Radiation Therapy and High Dose Corticosteroids for Elderly Patients (70 Years of Age and Older) Completed NCT00003278 Phase 2 dexamethasone
21 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
22 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
23 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
24 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
25 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
26 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
27 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
28 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
29 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
30 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
31 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
32 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
33 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
34 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
35 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
36 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
37 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
38 BUSULFAN AND CYCLOPHOSPHAMIDE FOR CYTOREDUCTION OF PATIENTS WITH ACUTE AND CHRONIC LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION WHO CANNOT BE TREATED WITH TOTAL BODY IRRADIATION Completed NCT00002502 Phase 2 busulfan;cyclophosphamide;cytarabine
39 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
40 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
41 Combined Intravitreal Methotrexate and R2 Regimen Followed by Lenalidomide Maintenance in Newly-diagnosed Primary Vitreoretinal Lymphoma Recruiting NCT03746223 Phase 2 Methotrexate;Rituximab;Lenalidomide
42 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
43 Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
44 Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma Active, not recruiting NCT02542514 Phase 2 Ibrutinib
45 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Active, not recruiting NCT01805037 Phase 1, Phase 2 brentuximab vedotin
46 A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA Terminated NCT01769222 Phase 1, Phase 2
47 Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma Terminated NCT00089076 Phase 1, Phase 2
48 A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen Terminated NCT00074165 Phase 2 Rituxan;Cyclophosphamide;Etoposide;Etoposide phosphate;Carboplatin;Sodium thiosulfate;Neupogen;Neulasta;Cytarabine
49 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
50 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus

Search NIH Clinical Center for Intraocular Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intraocular Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Intraocular Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Intraocular Lymphoma:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: intraocular lymphoma

Genetic Tests for Intraocular Lymphoma

Genetic tests related to Intraocular Lymphoma:

# Genetic test Affiliating Genes
1 Intraocular Lymphoma 29

Anatomical Context for Intraocular Lymphoma

MalaCards organs/tissues related to Intraocular Lymphoma:

40
B Cells, Brain, Eye, T Cells, Liver, Retina, Bone

Publications for Intraocular Lymphoma

Articles related to Intraocular Lymphoma:

(show top 50) (show all 418)
# Title Authors PMID Year
1
Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid. 54 61
19484437 2009
2
IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. 61 54
17591896 2007
3
[Diagnostic value of interleukin-10 and interleukin-6 in the vitreous of intraocular malignant lymphoma patients]. 54 61
15242071 2004
4
Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. 54 61
12578791 2003
5
Using interleukin 10 to interleukin 6 ratio to distinguish primary intraocular lymphoma and uveitis. 54 61
10476821 1999
6
Primary intraocular lymphoma with a low interleukin 10 to interleukin 6 ratio and heterogeneous IgH gene rearrangement. 54 61
10496399 1999
7
Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. 61 54
9298057 1997
8
Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. 54 61
7485372 1995
9
Logistic Regression Classification of Primary Vitreoretinal Lymphoma versus Uveitis by Interleukin 6 and Interleukin 10 Levels. 61
32197914 2020
10
Choroidal neovascularization as a complication of primary vitreous retinal lymphoma. 61
32551977 2020
11
[Resection of a submacular traction membrane due to significant visual impairment : Case report]. 61
32504126 2020
12
Rituximab-Associated Retinal Occlusive Vasculopathy: A Case Report and Literature Review. 61
31314626 2020
13
Neuro-Ophthalmic Manifestations of Intracranial Malignancies. 61
32282510 2020
14
Primary intraocular lymphoma. 61
31899059 2020
15
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens. 61
31972811 2020
16
Changes in Etiology of Uveitis in a Single Center in Japan. 61
32068467 2020
17
Analysis of inflammatory mediators in the vitreous humor of eyes with pan-uveitis according to aetiological classification. 61
32066796 2020
18
Clinical and histopathological classification of feline intraocular lymphoma. 61
31328872 2020
19
THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA. 61
29210961 2020
20
Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas? 61
31611509 2019
21
Cornea Findings of Spectral Domain Anterior Segment Optical Coherence Tomography in Uveitic Eyes of Various Etiologies. 61
31335529 2019
22
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens. 61
31613837 2019
23
Clinical and etiologic characteristics of de novo uveitis in patients aged 60 years and above: experience of a French tertiary center. 61
31312906 2019
24
Diagnostic dilemma of ocular lymphoma. 61
31175115 2019
25
Pomalidomide in primary intraocular lymphoma. 61
30632826 2019
26
[Diagnostic vitrectomy in intraocular inflammations: A retrospective series]. 61
31084938 2019
27
Primary Choroidal Lymphoma Diagnosed with 27-Gauge Pars Plana Vitrectomy Choroidal Biopsy. 61
31692619 2019
28
CLINICAL PATHOLOGIC CORRELATION OF SARCOIDOSIS-ASSOCIATED MULTIFOCAL CHORIORETINITIS IN AN ELDERLY PATIENT. 61
28145942 2019
29
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). 61
31987280 2019
30
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. 61
30698644 2019
31
Flow cytometry immunophenotyping of vitreous specimens does not contribute to diagnosis of lymphoma without supporting morphologic features. 61
30485724 2019
32
Vertical Hyperreflective Lesions on Optical Coherence Tomography in Vitreoretinal Lymphoma. 61
30489610 2019
33
Primary vitreoretinal lymphoma. 61
30930667 2019
34
Primary vitreoretinal lymphoma: prevalence, impact, and management challenges. 61
30858685 2019
35
Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma. 61
30320386 2019
36
Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma. 61
30416173 2018
37
Clinical features and outcomes of secondary intraocular lymphoma. 61
29143310 2018
38
An unusual case report of primary vitreoretinal lymphoma. 61
30255824 2018
39
Epidemiology of uveitis (2013-2015) and changes in the patterns of uveitis (2004-2015) in the central Tokyo area: a retrospective study. 61
30068311 2018
40
Improved design and characterization of PLGA/PLA-coated Chitosan based micro-implants for controlled release of hydrophilic drugs. 61
29857096 2018
41
Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report. 61
29954352 2018
42
Ocular/adnexal lymphoma: dissimilar to systemic lymphoma. 61
28837797 2018
43
[Primary vitreoretinal lymphoma]. 61
29589147 2018
44
Interleukins in the Diagnosis of Intraocular Lymphoma: Do We Still Need Histologic Confirmation? 61
29561391 2018
45
Intravitreal rituximab for the treatment of a secondary intraocular relapse of a large B-cell lymphoma. 61
29577096 2018
46
Clinical and pathological classification of canine intraocular lymphoma. 61
28714087 2018
47
Intraocular Lymphoma or Infection? Subretinal Aspirate Confirms the Diagnosis. 61
30057839 2018
48
Intraocular Lymphoma Masquerading as Recurrent Iridocyclitis: Findings Based on in vivo Confocal Microscopy. 61
29099641 2018
49
Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes. 61
27438792 2018
50
[Multi-session stereotactic radiotherapy in the treatment of recurrent B-cell primary intraocular lymphoma (a case report)]. 61
29953086 2018

Variations for Intraocular Lymphoma

Expression for Intraocular Lymphoma

Search GEO for disease gene expression data for Intraocular Lymphoma.

Pathways for Intraocular Lymphoma

Pathways related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.98 IL10 CXCR5 CXCR4 CXCL12 BCL2
2
Show member pathways
12.48 IL10 CXCR5 CXCR4 CXCL12
3
Show member pathways
11.96 IL10 CXCR4 CXCL12 BCL2
4 11.61 PAX5 IL10 CXCR5 CXCR4 CXCL12 BCL6
5
Show member pathways
11.59 IL10 CXCR5 CXCR4 CXCL12
6 11.55 IL10 BCL6 BCL2
7
Show member pathways
11.08 IL10 BCL2
8 10.99 CXCR4 CXCL12
9 10.97 FOLR1 ABCC1
10 10.87 IL10 BCL2
11 10.77 BCL2 ABCC1
12
Show member pathways
10.67 FOLR1 ABCC1
13 10.16 BCL2 ABCC1

GO Terms for Intraocular Lymphoma

Cellular components related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 IGHV4-38-2 CXCR5 CXCR4 CXCL12

Biological processes related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.84 IL10 CXCR5 CXCR4 CXCL12
2 chemotaxis GO:0006935 9.69 CXCR5 CXCR4 CXCL12
3 B cell differentiation GO:0030183 9.58 IL10 BCL6 BCL2
4 negative regulation of mitotic cell cycle GO:0045930 9.57 IL10 BCL2
5 response to radiation GO:0009314 9.56 CXCL12 BCL2
6 B cell proliferation GO:0042100 9.55 IL10 BCL2
7 leukocyte chemotaxis GO:0030595 9.52 IL10 CXCR5
8 positive regulation of calcium ion import GO:0090280 9.49 TRPV2 CXCL12
9 axon regeneration GO:0031103 9.48 FOLR1 BCL2
10 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.46 CXCR4 CXCL12
11 detection of mechanical stimulus involved in sensory perception of pain GO:0050966 9.43 CXCR4 CXCL12
12 regulation of programmed cell death GO:0043067 9.37 CXCR4 BCL2
13 type 2 immune response GO:0042092 9.32 IL10 BCL6
14 telencephalon cell migration GO:0022029 9.26 CXCR4 CXCL12
15 response to ultrasound GO:1990478 9.16 CXCR4 CXCL12
16 regulation of calcium ion transport GO:0051924 9.13 CXCR4 CXCL12 BCL2
17 cell chemotaxis GO:0060326 8.92 CXCR5 CXCR4 CXCL12 ABCC1

Molecular functions related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine binding GO:0019956 9.26 CXCR5 CXCR4
2 C-C chemokine binding GO:0019957 9.16 CXCR5 CXCR4
3 C-C chemokine receptor activity GO:0016493 8.96 CXCR5 CXCR4
4 C-X-C chemokine receptor activity GO:0016494 8.62 CXCR5 CXCR4

Sources for Intraocular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....